Hyperthermia and Ultrasound Based Ablative Cancer Treatments - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage policy update (effective 10/01/2026) establishing coverage criteria for hyperthermia and ultrasound-based ablative cancer treatments. The policy provides specific medical necessity requirements for HIPEC, ILI/ILP, and laser therapy procedures, with defined billing codes and clinical indications that billing teams must verify before claim submission.